In gliomas, IDH1 mutation, 1p/19q co-deletion, and MGMT promoter methylation can be routinely assessed and the results of these analyses help to refine the diagnosis and prognosis, and improve the treatment of the affected patients (for review see [2]). This evidence concerns the gene MGMT and central nervous system cancer.